hi Shlok Heres the thing As mentioned David has been in contact with the FDA and the Europeans.. re ath434 trial with the GOLD standard trial design with placebo. Where changes to the trial have been made… Prof C “ I know the MSA community welcomes this exciting advancement” Then in the US Huge $$$ were raised by JP Morgan Chase… were they objective? {They have a very large bio department doing DD)
David : We now have evidence that targeting excess liability in neurogenerative disease etc.
So im not arguing with you Can you seriously interpret clinical data better than Prof C and David who has the green light to take other drugs to commercialisation.from the FDA ?
ATH Price at posting:
0.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)